Notice of Exempt Offering of Securities, item 06b

> X0707 D LIVE 0000868278 ProPhase Labs, Inc. 621 N. SHADY RETREAT ROAD DOYLESTOWN PA PENNSYLVANIA 18901 2153450919 DELAWARE QUIGLEY CORP Corporation true Ted Karkus 621 N. Shady Retreat Rd. Doylestown PA PENNSYLVANIA 18901 Executive Officer Director Robert V. Cuddihy, Jr. 621 N. Shady Retreat Rd. Doylestown PA PENNSYLVANIA 18901 Executive Officer Mark Burnett 621 N. Shady Retreat Rd. Doylestown PA PENNSYLVANIA 18901 Director Mark Leventhal 621 N. Shady Retreat Rd. Doylestown PA PENNSYLVANIA 18901 Director Louis Gleckel 621 N. Shady Retreat Rd. Doylestown PA PENNSYLVANIA 18901 Director James McCubbin 621 N. Shady Retreat Rd. Doylestown PA PENNSYLVANIA 18901 Director Jason Barr 621 N. Shady Retreat Rd. Doylestown PA PENNSYLVANIA 18901 Director Pharmaceuticals $5,000,001 - $25,000,000 06b false 2015-12-11 false true true true false 0 3000000 1500000 1500000 false 2 0 0 0 false ProPhase Labs, Inc. /s/ Robert V. Cuddihy, Jr. Robert V. Cuddihy, Jr. CEO 2015-12-24

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever ProPhase Labs makes a similar move, sign up!

Other recent filings from the company include the following:

ProPhase Labs's Chief Financial Officer just picked up 360,000 shares - Sept. 15, 2017
Tender offer statement by Issuer - Aug. 25, 2017
Departure of Directors or Certain - Aug. 24, 2017

Auto Refresh

Feedback